{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:27:17Z","timestamp":1783636037640,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["874735"],"award-info":[{"award-number":["874735"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["109986"],"award-info":[{"award-number":["109986"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["01142052310005"],"award-info":[{"award-number":["01142052310005"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Viruses"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>How B-cell responses towards seasonal human coronaviruses (sHCoVs) impacted those towards SARS-CoV-2 has been widely studied, yet potential reverse effects are ill-defined. We compared sHCoV immune responses between cross-sectional pre-pandemic and end-pandemic cohorts of immunocompetent adults. We assessed Spike (S) reactive IgG and IgA serum and B-cell responses towards sHCoVs and dominant SARS-CoV-2 variants, and evaluated their contribution to OC43 neutralization. Pre-pandemic individuals were uniformly sHCoV IgG and IgA seropositive, yet SARS-CoV-2 S-reactivity was negligible. End-pandemic donors, had predominant SARS-CoV-2 responses that in part cross-reacted with sHCoV which accounted for higher serum NL63, HKU1 and OC43 antibody levels. This effect was strongest for OC43 S2 and this cross-reactive response contributed to OC43 serum neutralization. We conclude that SARS-CoV-2-specific immune responses impacted sHCoVs responses, particularly for OC43. This could have implications for immune protection and offers insights for the development of pan-coronavirus treatments and vaccines.<\/jats:p>","DOI":"10.1038\/s44298-026-00185-6","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:29:22Z","timestamp":1773912562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SARS-CoV-2 crossreactive B-cells outnumber seasonal coronavirus spike-specific clones at the end of the COVID-19 pandemic"],"prefix":"10.1038","volume":"4","author":[{"given":"Cristina","family":"Gonzalez-Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Aguilar-Bretones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Reinders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"van den Doel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batuhan","family":"Bekki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"van Gorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Hugo M.","family":"van der Kuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Haagmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine H.","family":"GeurtsVanKessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion P. G.","family":"Koopmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory D.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit J.","family":"van Gils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijsbert P.","family":"van Nierop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"185_CR1","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e15 (2020).","journal-title":"Cell"},{"key":"185_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103495","volume":"70","author":"T Woudenberg","year":"2021","unstructured":"Woudenberg, T. et al. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. EBioMedicine 70, 103495 (2021).","journal-title":"EBioMedicine"},{"key":"185_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-433","volume":"13","author":"W Zhou","year":"2013","unstructured":"Zhou, W., Wang, W., Wang, H., Lu, R. & Tan, W. First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhood. BMC Infect. Dis. 13, 433 (2013).","journal-title":"BMC Infect. Dis."},{"key":"185_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/infdis\/jiaa161","volume":"222","author":"AS Monto","year":"2020","unstructured":"Monto, A. S. et al. Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan. J. Infect. Dis. 222, 9\u201316 (2020).","journal-title":"J. Infect. Dis."},{"key":"185_CR5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3201\/eid2607.200841","volume":"26","author":"NMA Okba","year":"2020","unstructured":"Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2\u2212specific antibody responses in coronavirus disease patients. Emerg. Infect. Dis. J. 26, 1478 (2020).","journal-title":"Emerg. Infect. Dis. J."},{"key":"185_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"185_CR7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.immuni.2023.02.005","volume":"56","author":"P Zhou","year":"2023","unstructured":"Zhou, P. et al. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Immunity 56, 669\u2013686.e7 (2023).","journal-title":"Immunity"},{"key":"185_CR8","doi-asserted-by":"publisher","unstructured":"Harris, C. et al. Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes. https:\/\/doi.org\/10.1128\/jvi.00465-25 (2025).","DOI":"10.1128\/jvi.00465-25"},{"key":"185_CR9","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1080\/21645515.2020.1740560","volume":"16","author":"WH Chen","year":"2020","unstructured":"Chen, W. H., Hotez, P. J. & Bottazzi, M. E. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Hum. Vaccin Immunother. 16, 1239\u20131242 (2020).","journal-title":"Hum. Vaccin Immunother."},{"key":"185_CR10","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042.e21 (2020).","journal-title":"Cell"},{"key":"185_CR11","doi-asserted-by":"publisher","first-page":"e162192","DOI":"10.1172\/JCI162192","volume":"133","author":"M Aguilar-Bretones","year":"2023","unstructured":"Aguilar-Bretones, M., Fouchier, R. A. M., Koopmans, M. P. G. & van Nierop, G. P. Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity. J. Clin. Investig. 133, e162192 (2023).","journal-title":"J. Clin. Investig."},{"key":"185_CR12","doi-asserted-by":"publisher","first-page":"e150613","DOI":"10.1172\/JCI150613","volume":"131","author":"M Aguilar-Bretones","year":"2021","unstructured":"Aguilar-Bretones, M. et al. Seasonal coronavirus\u2013specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19. J. Clin. Investig. 131, e150613 (2021).","journal-title":"J. Clin. Investig."},{"key":"185_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23977-1","volume":"12","author":"T Aydillo","year":"2021","unstructured":"Aydillo, T. et al. Immunological imprinting of the antibody response in COVID-19 patients. Nat. Commun. 12, 3781 (2021).","journal-title":"Nat. Commun."},{"key":"185_CR14","first-page":"572","volume":"104","author":"T Francis","year":"1960","unstructured":"Francis, T. On the doctrine of original antigenic sin. Proc. Am. Philos. Soc. 104, 572\u2013578 (1960).","journal-title":"Proc. Am. Philos. Soc."},{"key":"185_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105105","volume":"25","author":"AHA Lavell","year":"2022","unstructured":"Lavell, A. H. A. et al. Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection. iScience 25, 105105 (2022).","journal-title":"iScience"},{"key":"185_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado7588","volume":"16","author":"DJ Bean","year":"2025","unstructured":"Bean, D. J. et al. Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence. Sci. Transl. Med. 16, eado7588 (2025).","journal-title":"Sci. Transl. Med."},{"key":"185_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37928","volume":"10","author":"M Garziano","year":"2024","unstructured":"Garziano, M. et al. SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43. Heliyon 10, e37928 (2024).","journal-title":"Heliyon"},{"key":"185_CR18","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.70330","volume":"10","author":"M Grobben","year":"2021","unstructured":"Grobben, M. et al. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. Elife 10, e70330 (2021).","journal-title":"Elife"},{"key":"185_CR19","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.75228","volume":"11","author":"AR Crowley","year":"2022","unstructured":"Crowley, A. R. et al. Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike. Elife 11, e75228 (2022).","journal-title":"Elife"},{"key":"185_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.chom.2021.12.005","volume":"30","author":"C-Y Lin","year":"2022","unstructured":"Lin, C.-Y. et al. Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. Cell Host Microbe 30, 83\u201396.e4 (2022).","journal-title":"Cell Host Microbe"},{"key":"185_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24979-9","volume":"12","author":"N Ortega","year":"2021","unstructured":"Ortega, N. et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nat. Commun. 12, 4740 (2021).","journal-title":"Nat. Commun."},{"key":"185_CR22","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.cell.2021.02.010","volume":"184","author":"EM Anderson","year":"2021","unstructured":"Anderson, E. M. et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell 184, 1858\u20131864.e10 (2021).","journal-title":"Cell"},{"key":"185_CR23","doi-asserted-by":"publisher","first-page":"790334","DOI":"10.3389\/fimmu.2022.790334","volume":"13","author":"M Miyara","year":"2022","unstructured":"Miyara, M. et al. Pre-COVID-19 immunity to common cold human coronaviruses induces a recall-type IgG response to SARS-CoV-2 antigens without cross-neutralisation. Front. Immunol. 13, 790334 (2022).","journal-title":"Front. Immunol."},{"key":"185_CR24","unstructured":"Reukers, D. F. M. et al. Annual Report Surveillance of Acute Respiratory Infections in the Netherlands: Winter 2022\/2023 SARS-CoV-2, Influenza Virus, RSV and Other Respiratory Viruses. (2023)."},{"key":"185_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.virol.2007.04.035","volume":"367","author":"W Li","year":"2007","unstructured":"Li, W. et al. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology 367, 367\u2013374 (2007).","journal-title":"Virology"},{"key":"185_CR26","doi-asserted-by":"publisher","first-page":"594439","DOI":"10.3389\/fmed.2020.594439","volume":"7","author":"ME Cueno","year":"2021","unstructured":"Cueno, M. E. & Imai, K. Structural comparison of the SARS CoV 2 spike protein relative to other human-infecting coronaviruses. Front. Med. 7, 594439 (2021).","journal-title":"Front. Med."},{"key":"185_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","volume":"23","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 23, 189\u2013199 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"185_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41392-023-01472-x","volume":"8","author":"L Guo","year":"2023","unstructured":"Guo, L. et al. Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines. Signal. Transduct. Target Ther. 8, 197 (2023).","journal-title":"Signal. Transduct. Target Ther."},{"key":"185_CR29","doi-asserted-by":"publisher","first-page":"e13309","DOI":"10.1111\/irv.13309","volume":"18","author":"RSH Lee","year":"2024","unstructured":"Lee, R. S. H. et al. Cross-reactive antibody responses to coronaviruses elicited by SARS-CoV-2 infection or vaccination. Influenza Other Respir. Viruses 18, e13309 (2024).","journal-title":"Influenza Other Respir. Viruses"},{"key":"185_CR30","doi-asserted-by":"publisher","first-page":"e42171","DOI":"10.1016\/j.heliyon.2025.e42171","volume":"11","author":"Z Hasan","year":"2025","unstructured":"Hasan, Z. et al. Pre-existing IgG antibodies to HCoVs NL63 and OC43 Spike increased during the pandemic and after COVID-19 vaccination. Heliyon 11, e42171 (2025).","journal-title":"Heliyon"},{"key":"185_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40960-0","volume":"14","author":"AP Hederman","year":"2023","unstructured":"Hederman, A. P. et al. SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations. Nat. Commun. 14, 5171 (2023).","journal-title":"Nat. Commun."},{"key":"185_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32232-0","volume":"13","author":"M Claireaux","year":"2022","unstructured":"Claireaux, M. et al. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike. Nat. Commun. 13, 4539 (2022).","journal-title":"Nat. Commun."},{"key":"185_CR33","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1126\/science.abj3321","volume":"373","author":"D Pinto","year":"2021","unstructured":"Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix\u2013specific human antibody. Science 373, 1109\u20131116 (2021).","journal-title":"Science"},{"key":"185_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109929","volume":"37","author":"C-L Hsieh","year":"2021","unstructured":"Hsieh, C.-L. et al. Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Rep. 37, 109929 (2021).","journal-title":"Cell Rep."},{"key":"185_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21968-w","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nat. Commun. 12, 1715 (2021).","journal-title":"Nat. Commun."},{"key":"185_CR36","doi-asserted-by":"crossref","unstructured":"Sun, S. et al. Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses. Front. Immunol. 16-2025, 1541269 (2025).","DOI":"10.3389\/fimmu.2025.1541269"},{"key":"185_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.medj.2021.01.005","volume":"2","author":"E Pradenas","year":"2021","unstructured":"Pradenas, E. et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med 2, 313\u2013320.e4 (2021).","journal-title":"Med"},{"key":"185_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21444-5","volume":"12","author":"AK Wheatley","year":"2021","unstructured":"Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162 (2021).","journal-title":"Nat. Commun."},{"key":"185_CR39","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1473-3099(23)00140-8","volume":"23","author":"NH Tan","year":"2023","unstructured":"Tan, N. H. et al. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial. Lancet Infect. Dis. 23, 901\u2013913 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"185_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60048-9","volume":"10","author":"B Westerhuis","year":"2020","unstructured":"Westerhuis, B. et al. Specific memory B cell response in humans upon infection with highly pathogenic H7N7 avian influenza virus. Sci. Rep. 10, 3152 (2020).","journal-title":"Sci. Rep."},{"key":"185_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2249.2010.04206.x","volume":"162","author":"H Morbach","year":"2010","unstructured":"Morbach, H., Eichhorn, E. M., Liese, J. G. & Girschick, H. J. Reference values for B cell subpopulations from infancy to adulthood. Clin. Exp. Immunol. 162, 271\u2013279 (2010).","journal-title":"Clin. Exp. Immunol."},{"key":"185_CR42","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/eji.200839129","volume":"39","author":"D Pinna","year":"2009","unstructured":"Pinna, D., Corti, D., Jarrossay, D., Sallusto, F. & Lanzavecchia, A. Clonal dissection of the human memory B-cell repertoire following infection and vaccination. Eur. J. Immunol. 39, 1260\u20131270 (2009).","journal-title":"Eur. J. Immunol."},{"key":"185_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1089\/hyb.1983.2.91","volume":"2","author":"HA Coller","year":"1983","unstructured":"Coller, H. A. & Coller, B. S. Statistical analysis of repetitive subcloning by the limiting dilution technique with a view toward ensuring hybridoma monoclonality. Hybridoma 2, 91\u201396 (1983).","journal-title":"Hybridoma"},{"key":"185_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00886-0","volume":"9","author":"M Aguilar-Bretones","year":"2024","unstructured":"Aguilar-Bretones, M. et al. SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity. npj Vaccines 9, 93 (2024.","journal-title":"npj Vaccines"}],"container-title":["npj Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00185-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00185-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00185-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:02:23Z","timestamp":1773918143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00185-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["185"],"URL":"https:\/\/doi.org\/10.1038\/s44298-026-00185-6","relation":{},"ISSN":["2948-1767"],"issn-type":[{"value":"2948-1767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author M.Jv.G. is an Associate Editor of npj Vaccines. M.Jv.G. was not involved in the journal\u2019s review of, or decisions related to, this manuscript. The rest of the authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}